| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999789 | Urologic Oncology: Seminars and Original Investigations | 2015 | 9 Pages |
Abstract
FABP7 is overexpressed in ccRCC and promotes cell growth by the activation of ERK and Stat3 signaling pathways. Evidence from the clinical observations and experimental data suggests that FABP7 is a novel prognostic marker and potential therapeutic target for ccRCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jiancheng Ph.D., Zhuo Ph.D., Yule Ph.D., Yang Ph.D., Dapeng M.D., Guodong Ph.D., Lei Ph.D., Wenbin M.D., Xinyang M.S., Kaijie Ph.D., Dalin M.D.,